Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-methyl-2'-deoxypseudouridine is a synthetic nucleoside analog structurally related to pseudouridine and thymidine. It features a methyl group at the C5 position and a deoxy modification at the ribose sugar, making it distinct from naturally occurring uridines. This compound is classified as an experimental small molecule and has not been approved for clinical use. Its primary research application is as a substrate or ligand in studies of nucleoside metabolism, particularly involving nucleoside 2-deoxyribosyltransferase enzymes, which play roles in nucleotide salvage pathways. The compound may be used to investigate enzyme specificity, catalysis mechanisms, or as an intermediate in the synthesis of modified oligonucleotides for biochemical research[1][3][4][5]. No therapeutic mechanism of action or clinical indication has been established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-methyl-2'-deoxypseudouridine.